GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Compugen Ltd (XTAE:CGEN) » Definitions » Loans Receivable

Compugen (XTAE:CGEN) Loans Receivable : ₪0.00 Mil (As of Dec. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Compugen Loans Receivable?

Compugen's Loans Receivable for the quarter that ended in Dec. 2024 was ₪0.00 Mil.


Compugen Loans Receivable Historical Data

The historical data trend for Compugen's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compugen Loans Receivable Chart

Compugen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Compugen Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Compugen Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Compugen Loans Receivable Related Terms

Thank you for viewing the detailed overview of Compugen's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Compugen Business Description

Traded in Other Exchanges
Address
26 Harokmim Street, Building D, Azrieli Center, Holon, ISR, 5885849
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.